PET/CT helps gauge patient response to neoadjuvant chemotherapy

04/10/2013 | AuntMinnie.com (free registration)

A study presented at a radiology meeting found that FDG-PET/CT has the potential to predict patient response following neoadjuvant chemotherapy for breast cancer. Researchers said the results suggest the assessment could be useful for guiding treatment decisions. The researchers used Sinn scores and two algorithms to measure patient response. An 88% change in maximum standardized uptake value is the appropriate cutoff to distinguish lesions that respond to treatment, they reported.

View Full Article in:

AuntMinnie.com (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA
Sr Coordinator Clinical Research (US/TA/00/0073/SL) - 1400000AQX
Abbott
Santa Clara, CA
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA